Revenio Group Oyj

Major Shareholding Notification • Nov 27, 2019

Disclosure 377016

Revenio Group Oyj - Major shareholder announcements

Revenio Group Corporation: Notice pursuant to chapter 9, section 5 of the securities market act

Revenio Group Corporation, Stock Exchange Release, November 27, 2019 at 18:00 EET Notice pursuant to chapter 9, section 5 of the securities market act Revenio Group Corporation has November 24, 2019 received a notification of change in holdings in accordance with Chapter 9, Section 5 of the Securities Markets Act that William Demant Invest A/S's share of the total number of shares and voting rights in Revenio Group Corporation has increased to more than five per cent. William Demant Invest A/S now holds 2.192.838 shares in Revenio Group Corporation, which is 8.28 per cent of the company's shares and voting rights. The total number of Revenio Group Corporation's shares recorded in the trade register is 26.468.530 shares. Revenio Group Corporation Robin Pulkkinen, CFO, tel. +358 50 505 9932 robin.pulkkinen@revenio.fi www.revenio.fi DISTRIBUTION: Nasdaq Helsinki Oy Financial Supervisory Authority (FIN-FSA) Principal media www.revenio.fi The Revenio Group in brief Revenio is a health tech group operating on the international market and a global leader in solutions for the diagnostics of the eye. The common denominators of Revenio's business operations include patient-led screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early -stage detection of diseases with significance for public health. The goal is to create better quality of life through health technology solutions that enable more efficient diagnostics. The focus of the Group is on the early detection of glaucoma, diabetic retinopathy, and macular degeneration, and the monitoring of these during the treatment process. Revenio’s Research function focuses on the commercialization of systems that support the diagnosis of skin cancer and asthma and planning their treatment. The Revenio Group comprises Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, CenterVue Inc., Revenio Research Oy, and Oscare Medical Oy. In 2018, the Revenio Group's net sales totaled EUR 30.7 million, while its EBITDA stood at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.